B-Vaxx was mentioned in the Pharma Letter as one of the VAX in trials. But not in the 4C, maybe because it is financed by US comps/government Uni Grants.
Anyway, focus is on Her, PD1 and CF33 which should catapult IMU into a recognized pharma orbit.
GLTA
Ann: Appendix 4C - quarterly, page-6
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
0.002(3.92%) |
Mkt cap ! $387.9M | |||
| Open | High | Low | Value | Volume |
| 5.1¢ | 5.3¢ | 5.0¢ | $605.4K | 11.73M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 455000 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 1913821 | 7 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |